Full
Outline
To explore the effect of Cinobufagin Capsule combined with metronomic chemotherapy on tumor microenvironment and chemokine receptor 7（CXCR7）and CXCR4 in patients with non-small cell lung cancer（NSCLC）.
One hundred and twenty-two NSCLC patients admitted to the hospital from January 2022 to October 2023 were selected and randomly assigned into two groups using the random number table method, each with 61 cases. The control group was given 3 cycles of metronomic chemotherapy（pemetrexed + cisplatin）. Based on this, The study group was treated with Cinobufagin Capsule for 9 weeks. After treatment, the clinical efficacy, tumor markers[carcinoembryonic antigen（CEA）, cytokeratin 19 fragment（CYFRA21-1）, carbohydrate antigen 125（CA125）], immune function indicators（CD3+, CD4+, CD8+）, positive expression rates of CXCR7 and CXCR4 and adverse reactions were compared between two groups.
The object response rate and disease control rate were 40.98% and 62.30% in the control group, which were 67.21% and 86.89% in the study group, with statistical difference（P<0.05）. The serum levels of CEA, CYFRA21-1 and CA125 showed a reduction in both groups after treatment, and the three tumor markers were notably lower in the study group than those in the control group（P<0.05）. A decline in CD3+, CD4+ and CD4+/CD8+ and an increase in CD8+ were detected in both groups after treatment（P<0.05）, and the study group had higher levels of CD3+, CD4+ and CD4+/CD8+ and lower CD8+ lower than those of the control group（P<0.05）. The positive rates of CXCR7 and CXCR4 showed a decrease in both groups after treatment, and were lower in the study group than those in the control group（P<0.05）. The overall incidence rate of adverse reactions including nausea, vomiting, neutropenia, thrombocytopenia and liver function damage in the study group was lower than that in the control group（P<0.05）.
The application of Cinobufagin Capsule combined with metronomic chemotherapy in NSCLC patients can effectively ameliorate the tumor microenvironment, and reduce the positive rates of CXCR7 and CXCR4, which is worthy of promotion.
91
16
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
